YL-17231
RAS-driven Cancer
Phase 1Active
Key Facts
About 280Bio
Developing oral RAS-targeted therapies for cancers driven by KRAS, NRAS, and HRAS mutations.
View full company profileRAS-driven Cancer
Developing oral RAS-targeted therapies for cancers driven by KRAS, NRAS, and HRAS mutations.
View full company profile